VVM Vivomedica

    RNS Number : 8915C
  Vivomedica PLC
  08 September 2008
   

 For immediate release  8 September 2008
    
    VivoMedica plc

    ("VivoMedica" or the "Company")

    Annual General Meeting Statement

    VivoMedica plc (AIM:VVM) the pharmaware company, will hold its Annual General Meeting today at 9.00 am at the offices of Buchanan
Communications, 45 Moorfields, London EC2Y 9AE. 

    At the meeting, Peter Leyland, CEO of VivoMedica will give the following update on the development of the Company's two core technology
products, DrugPrint� and PathScoreTM:

    DrugPrint� expansion into Human Stem Cells

    VivoMedica was delighted to announce its collaboration with Cellartis AB (Goteborg) in June this year, to explore the combination of
human Stem Cells (hSC) and the sophisticated analytical capabilities of VivoMedica's DrugPrint� system.

    The Company strongly believes that the use of hSC are the way forward in the safety evaluation of medicines, particularly in the
successful development of new drugs where the cost of failure is exceptionally high and can prohibit further clinical development of
innovative medicines. Our extensive market research indicates that this view is supported by a wide industry consensus, creating a market
opportunity that VivoMedica is now well placed to exploit.

    VivoMedica's intention is to be a leading player in the safety evaluation of medicines using hSC. Cellartis is the world's largest
single source of defined hSC and has developed more than 30 well documented hSC lines. The collaboration is expected to yield discriminatory
power needed by the pharmaceutical and biotech industry and increasingly expected by the regulatory authorities. 

    DrugPrint� presented to leading scientific conference

    In July 2008, VivoMedica presented DrugPrint� data at the 6th International Conference on Substrate-Integrated micro-electrode arrays
(MEA) in Reutlingen, Germany. DrugPrint� is the Company's pre-clinical tool to identify drug-induced cardio-toxicity. At this leading
conference, which showcases state of the art micro-electrode array technologies, VivoMedica was afforded the opportunity to present the
increased discriminatory power of DrugPrint� to an influential academic and scientific peer group audience.  Feedback suggests that the
audience considered that the cardiac data presented was both interesting and of high quality. 

    Building on this success, VivoMedica will be presenting hSC derived DrugPrint� data at the forthcoming Safety Pharmacology Society
conference in Madison WI, USA, to further raise the profile and awareness of DrugPrint� in the pharmaceutical community.

    PathScoreTM partners shortlisted 

    We are pleased to provide an update on partnering discussions for PathScoreTM, the Company's computerised image analysis system with
patented applications that support cancer diagnosis and treatment pathways. The Company now has a shortlist of strategically important
potential partners for PathScoreTM and discussions are progressing well. It is envisaged that the partners will support the global
commercialisation of this transformational technology. 

    Commenting on the update, Professor Sir Christopher Evans, Chairman VivoMedica said: " I am delighted that VivoMedica's world leading
innovations in drug discovery and other aspects of human medical research have recently been so well received by the pharmaceutical industry
and several global and medtech companies. Our safety data for drugs using our unique DrugPrint and human stem cells is unparalleled in this
industry and I am very excited at the prospects already developing for our world beating PathScore technology. There is plenty more to come
from VivoMedica in 2008".

    For further information, please contact:

 VivoMedica                                  01795 414460
 Peter Leyland, Chief Executive Officer
 Susan Veness, Finance Director

 Brewin Dolphin Investment Banking (NOMAD)  0845 270 8600
 Mark Brady / Alison Barrow

 Buchanan Communications                    020 7466 5000
 Diane Stewart / Catherine Breen / Tim
 Anderson



This information is provided by RNS
The company news service from the London Stock Exchange
 
  END 
 
AGMGGGGLVKDGRZM

Grafico Azioni Vivomedica (LSE:VVM)
Storico
Da Mag 2024 a Giu 2024

Grafico Azioni Vivomedica (LSE:VVM)
Storico
Da Giu 2023 a Giu 2024